Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas

• ClinicalTrials.gov Identifier: NCT05751798
• Recruitment Status: Recruiting
• First Posted: March 2, 2023
• Last Update Posted: March 2, 2023
• Sponsor: OSE Immunotherapeutics
• Information provided by (Responsible Party): OSE Immunotherapeutics

Study Description

Brief Summary:

This is a phase 1/2, multicenter, dose-finding and dose expansion study of OSE-279, a PD-1 blocking monoclonal antibody, in subjects with advanced solid tumors or lymphomas.

Condition or disease	Intervention/treatment	Phase
Solid Advanced Tumor; Lymphoma	Drug: OSE-279 100mg; Drug: OSE-279 300mg; Drug: OSE-279 500mg	Phase 1; Phase 2

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 24 participants
• Allocation: Non-Randomized
• Intervention Model: Sequential Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Multicenter, Phase 1/2, Dose-finding and Dose Expansion Study of OSE-279, a PD-1 Blocking Monoclonal Antibody, in Subjects With Advanced Solid Tumors or Lymphomas
• Actual Study Start Date: December 20, 2022
• Estimated Primary Completion Date: May 2024
• Estimated Study Completion Date: July 2024

Arms and Interventions

Arm	Intervention/treatment
Experimental: OSE-279 100 mg; Dose Level 1: OSE-279 100 mg	Drug: OSE-279 100mg; Human IgG4 mAb against PD-1
Experimental: OSE-279 300 mg; Dose Level 2: OSE-279 300 mg	Drug: OSE-279 300mg; Human IgG4 mAb against PD-1
Experimental: OSE-279 500 mg; Dose Level 3: OSE-279 500 mg	Drug: OSE-279 500mg; Human IgG4 mAb against PD-1

Outcome Measures

Primary Outcome Measures :

1. Occurrence of dose limiting toxicity (DLT) [ Time Frame: DLT observation period is defined as the first 21 days after receiving the 1st injection of OSE-279 (Cycle 1) ]
   Occurrence of dose limiting toxicity (DLT)

Secondary Outcome Measures :

1. Objective Response Rate (ORR) [ Time Frame: Through study completion, an average of 1 year ]
   Objective Response Rate (ORR): complete response (CR) and partial response (PR), based on RECIST 1.1/RECIL and iRECIST
2. Disease Control Rate (DCR: CR, PR and SD) [ Time Frame: Through study completion, an average of 1 year ]
   Disease Control Rate (DCR): complete response (CR), partial response (PR) and stable disease (SD) based on RECIST 1.1/RECIL and iRECIST
3. Time to response [ Time Frame: From start of treatment until date of first occurence of response (CR or PR based on RECIST 1.1/RECIL and iRECIST), an average of 1 year ]
   Time to response
4. Duration of response (DR) [ Time Frame: From the first assessment of CR or PR until the date of the first occurrence of PD, or until the date of death (up to 1 year) ]
   Duration of response (DR)
5. Progression Free Survival (PFS) [ Time Frame: From start of treatment until date of progression based on RECIST 1.1/RECIL and iRECIST or date of death (up to 1 year) ]
   Progression Free Survival (PFS)
6. DCR at 12 weeks (CR+PR+SD) [ Time Frame: Up to 12 weeks ]
   DCR at 12 weeks (CR+PR+SD)
7. Overall Survival (OS) [ Time Frame: From start of treatment to Death (up to 2 years) ]
   Overall Survival (OS)

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria (I):

• I-1. Male or female adult patients.
• I-2. Signed and dated informed consent form (ICF) prior to any trial-specific procedures. Patients should be able and willing to comply with study visits and procedures as per protocol.
• I-3. ECOG performance status 0-1.

• I-4. Tumor type:

  1. advanced solid tumors or lymphomas for which an anti PD-1/PD-L1 has shown efficacy (e.g., with high microsatellite instability or MSI-H) but is not available in the center/country (no marketing authorization, no reimbursement, no early access program, etc.) or;
  2. rare tumors with reported significant activity of anti-PD-1 (e.g., Tertiary Lymphoid Structures positive or TLS+ sarcomas, alveolar soft part sarcomas, etc.), or;
  3. PD-L1 positive tumors.
• I-5. Prior treatment with at least one line of systemic therapy and no standard of care available.
• I-6. Evaluable or measurable disease according to RECIST 1.1/RECIL.

• I-7. Adequate organ function:

  1. Bone marrow: neutrophils ≥ 1.5 x 109/L, hemoglobin ≥ 90 g/L, platelets ≥ 100 x 109/L.
  2. Renal function: serum creatinine ≤ 1.5 ULN or CKD-EPI creatinine clearance ≥ 30 mL/min.
  3. Liver function: AST and ALT ≤ 3 ULN, bilirubin ≤ 1.5 ULN. In case of liver metastasis: AST and ALT ≤ 5 ULN. For patients with Gilbert's syndrome total bilirubin ≤ 3 ULN or direct bilirubin ≤ 1.5 ULN.
• I-8. Patients must be affiliated to a social security system or an equivalent system, if applicable as per local regulations.

Non-Inclusion Criteria (NI):

• NI-1. Patient eligible to surgical resection or another approved therapeutic regimen known to provide clinical benefit.
• NI-2. Patient previously treated with an approved or investigational anti-PD-1/PD-L1.
• NI-3. Patient with active autoimmune disease or a documented history of autoimmune disease requiring systemic treatment (i.e., corticosteroids or immunosuppressive drugs); except autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone, controlled hypophysitis, controlled Type 1 diabetes mellitus on a stable insulin regimen, vitiligo, resolved childhood asthma/atopy, alopecia, or any chronic skin condition not requiring systemic therapy.
• NI-4. Patient participating in another clinical trial with a medicinal product.
• NI-5. Patients who have not recovered from adverse events (i.e., > Grade 1 according to CTCAE v5.0) due to prior treatment with anti-cancer agents with exception of Grade 2 neuropathy or any Grade alopecia. Lab values must be within the limits presented in criterion I-7.
• NI-6. Patients with known additional malignancy progressing or requiring active treatment. Basal cell carcinoma, squamous cell carcinoma of the skin, or in situ cervical cancer are not a non-inclusion criteria.
• NI-7. Patients with known active central nervous system metastases and/or carcinomatous meningitis. Patients with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least 4 weeks prior to C1D1 and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids (at doses higher than 10 mg/day of methylprednisolone or equivalent) for at least 4 weeks prior C1D1.
• NI-8. Patients with active or history of non-infectious pneumonitis requiring steroids, or interstitial lung disease.
• NI-9. Patients with a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study.
• NI-10. Patients with a history of uncontrolled or symptomatic, clinically significant cardiovascular disease: stroke, myocardial infarction, angina pectoris, arrhythmias, congestive heart failure (NYHA Class >2), or myocarditis within 6 months prior to first study drug administration.
• NI-11. Patient with organ(s) transplanted including hematopoietic stem cell allograft.

• NI-12. Patients receiving or to be treated during the treatment period with one of the following forbidden treatments:

  1. Any anti-cancer systemic chemotherapy, targeted therapy or biological therapy including any immunotherapy not mentioned in this protocol. Washout prior to screening: chemotherapy: 3 weeks (6 weeks for nitrosourea), TKi or other small molecules: 2 weeks or 5 half-lives whichever is shortest, mAb: 4 weeks.
  2. Radiation therapy (washout prior to screening: 7 days prior to Cycle 1). Note: Radiation therapy to a symptomatic solitary non target lesion or to the brain may be allowed after consultation with Sponsor.
  3. Live vaccines. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, yellow fever, rabies, tuberculosis (BCG), and typhoid (oral) vaccines. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed.
  4. Recent major surgery within the previous 3 months.
  5. Systemic corticosteroids for any purpose other than to modulate symptoms from an event of clinical interest of suspected immunologic etiology. The use of physiologic doses of corticosteroids may be approved after consultation with the Sponsor. Immunosuppressive agents such as steroids should be tapered off before initiation of study treatment (except low-dose up to a total dose equivalent to prednisolone 10 mg/day).
• NI-13. Patients with hypersensitivity to OSE-279 or any of its excipients.
• NI-14. Patients with active tuberculosis (Mycobacterium tuberculosis).

• NI-15. Patients with:

  1. Active hepatitis B (defined as HBsAg+ and/or HBVc+ and HBV DNA+).
  2. Active hepatitis C (anti-HCV+ and HCV RNA+).
  3. Active HIV infection: HIV+ patients on highly active antiretroviral therapy (HAART) are eligible if PCR for HIV is negative at screening.
  4. Presence of signs/symptoms suggestive of active infection (including COVID-19 infection).
• NI-16. Patients with known psychiatric or substance abuse disorders that would interfere their ability to comply with protocol requirements.
• NI-17. WOCBP and men participating in the study (and their partners) must agree to follow the precautions to avoid gestational problems, by using highly efficient contraception throughout the study and until 4 months after the last administration of investigational treatment based on CTFG guidance. In addition, during this study period men should use condoms and avoid semen donation.
• NI-18. Women who are pregnant or breast-feeding or women/men expecting to conceive children within the projected duration of the trial, starting with the screening visit through 4 months after the last dose of trial treatment.
• NI-19. Vulnerable persons, if applicable as per local regulations, such as individuals under the protection of a legal guardian, pregnant or breastfeeding women, persons in custody by judicial or administrative decision, persons under psychiatric care without consent, persons admitted in a healthcare facility or social institution not for research purposes, minors, individuals unable to state their consent.

Contacts and Locations

Contacts

Contact: Caroline Chevalier, MSc, MPH; +33 630 842 002; caroline.chevalier@ose-immuno.com

Contact: Elena Medko, MD; +33 659 472 360; elena.medko@ose-immuno.com

Locations

Belgium

Institut Jules Bordet; Not yet recruiting

Anderlecht, Belgium, 1070

France

Centre Léon Bérard; Recruiting

Lyon, France, 69373

Centre Eugène Marquis; Not yet recruiting

Rennes, France, 35000

Institut de Cancerologie de l'Ouest; Not yet recruiting

Saint-Herblain, France, 44805

Oncopole; Not yet recruiting

Toulouse, France, 31059

Institut Gustave Roussy; Not yet recruiting

Villejuif, France, 94805

Sponsors and Collaborators

OSE Immunotherapeutics

More Information

• Responsible Party: OSE Immunotherapeutics
• ClinicalTrials.gov Identifier: NCT05751798
• Other Study ID Numbers: OSE-279-C101; 2022-001136-28 ( EudraCT Number )
• First Posted: March 2, 2023
• Last Update Posted: March 2, 2023
• Last Verified: February 2023

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Undecided

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by OSE Immunotherapeutics:

Solid advanced tumor; Lymphoma; Rare tumor; PD-L1 positive tumor; PD-1 blocking monoclonal antibody

Additional relevant MeSH terms:

Lymphoma; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases